Five-year results evaluating the healing of intrabony defects following treatment with A-PRF+ or EMD: a randomized controlled trial
Clinical Oral Investigations · 23.03.2026 · 30 (4)
DOI: 10.1007/s00784-026-06806-x ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Oral Investigations, online erschienen am 23.03.2026. Verfasst von Boróka Klára Csifó-Nagy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Periodontology, Faculty of Dentistry, Semmelweis University, Szentkirályi u. 47, Budapest, 1088, Hungary. csifo-nagy.boroka@semmelweis.…. Hauptthemen laut MEDLINE: Dental Enamel Proteins, Platelet-Rich Fibrin, Alveolar Bone Loss. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Semmelweis University.
Abstract (Originalsprache)
Objectives
The aim of the study was to clinically evaluate the long-term healing of intrabony periodontal defects treated with a new-generation platelet-rich fibrin (A-PRF+) compared with enamel matrix derivative (EMD). Materials and methods Thirty intrabony defects in 18 patients were randomly assigned to treatment with A-PRF+ (test, n = 15) or EMD (control, n = 15). Clinical parameters were assessed at baseline, 6 months, 1 year, and 5 years post-surgery. Clinical attachment level (CAL) was the primary outcome variable. Following full-thickness flap elevation, defect debridement, scaling, and root planning were performed. Defects were filled with A-PRF + or EMD according to group allocation and stabilized with sutures. At the 5-year follow-up, 26 defects in 14 patients were available for evaluation.
Results
Both treatment methods resulted in statistically significant PD reductions, respectively CAL gains after 6 months, and the results were maintained 5 years post-operatively. At 5 years no statistically significant differences were found between the two groups as the mean CAL gain was 2.92 ± 1.65 mm in the test group, and 3.84 ± 1.81 mm in the control group, respectively ( p < 0.05).
Conclusion
Within the limitations of this study, A-PRF+ demonstrated clinical outcomes comparable to EMD in the surgical treatment of intrabony periodontal defects, with stable long-term results. Clinical Relevance A-PRF + may represent a reliable autologous alternative for periodontal regeneration, offering favorable and stable clinical outcomes over a five-year period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Periodontology, Faculty of Dentistry, Semmelweis University, Szentkirályi u. 47, Budapest, 1088, Hungary. csifo-nagy.boroka@semmelweis.hu.
- Department of Periodontology, Faculty of Dentistry, Semmelweis University, Szentkirályi u. 47, Budapest, 1088, Hungary.
Förderung
- Semmelweis University
Zitieren
APA
Csifó-Nagy, B. K., Czufor, B., Sólyom, E., & Dőri, F. (2026). Five-year results evaluating the healing of intrabony defects following treatment with A-PRF+ or EMD: a randomized controlled trial. Clinical Oral Investigations, 30(4). https://doi.org/10.1007/s00784-026-06806-x
Vancouver
Csifó-Nagy BK, Czufor B, Sólyom E, Dőri F. Five-year results evaluating the healing of intrabony defects following treatment with A-PRF+ or EMD: a randomized controlled trial. Clinical Oral Investigations. 2026;30(4). doi:10.1007/s00784-026-06806-x
BibTeX
@article{CsifNagy2026,
author = {Csifó-Nagy, Boróka Klára and Czufor, Bálint and Sólyom, Eleonóra and Dőri, Ferenc},
title = {Five-year results evaluating the healing of intrabony defects following treatment with A-PRF+ or EMD: a randomized controlled trial},
journal = {Clinical Oral Investigations},
year = {2026},
volume = {30},
number = {4},
doi = {10.1007/s00784-026-06806-x}
}
EUVIMED